| Identification | More | [Name]
Cefoselis sulfate | [CAS]
122841-12-7 | [Synonyms]
CEFOSELIS SULFATE
FK 037
(6R-(6alpha,7beta(Z)))-7-(((2-Amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-((2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl)methyl)-8-oxo-5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid sulfate
Winsef | [EINECS(EC#)]
1533716-785-6 | [Molecular Formula]
C19H24N8O10S3 | [MDL Number]
MFCD00864819 | [Molecular Weight]
620.64 | [MOL File]
122841-12-7.mol |
| Hazard Information | Back Directory | [Description]
Cefoselis is a new fourth-generation cephalosporin and was launched
in Japan as a parenteral antibiotic for a variety of infections including
Staphylococcus aureus (particularly the methicillin-resistant MRSA) and
Pseudornonas aeruginosa. It can be prepared in 3 related ways, all using 2-
pyrazolomethyl-3-cephem-4-carboxylic as the key intermediate. In preclinical
studies, Cefolesis had better MIC50s than Ceftazidime against Streptococcus
pneurnoniae or Staphflococcus aureus (methicillin-sensitive MSSA or resistant
MRSA) and showed significant antibacterial activity against Citrobacter and
Enterobacter.
Cefolesis is well tolerated in clinical studies, being eliminated mainly via
glomerular filtration in humans. | [Originator]
Fujisawa (Japan) | [Uses]
antibiotic | [Definition]
ChEBI: Cefoselis sulfate is an azaheterocycle sulfate salt. It is functionally related to a member of cefoselis. | [Brand name]
Wincef |
|
|